Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | GBA1 | P04062 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080216 | 1.00 | CYP2D6 (0.74) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL24446594 | 1.00 | CYP2D6 (0.74) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL158567 | 0.98 | CYP3A4 (0.74) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL29729337 | 0.98 | CYP3A4 (0.74) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL22927420 | 0.90 | CYP2D6 (0.65) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL24446500 | 0.90 | CYP2D6 (0.65) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL24446428 | 0.89 | CYP2D6 (0.67) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL22927156 | 0.88 | CYP2D6 (0.67) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL10805559 | 0.86 | CYP2D6 (0.76) | CYP2D6LMNACYP1A2SLC6A4KCNH2 | |
| SCHEMBL10805556 | 0.86 | CYP2D6 (0.76) | CYP2D6LMNACYP1A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677825-A | Degradation agent of target host cell transmembrane serine protease 2 and synthetic method and application thereof | 杭州医学院 | 2023-02-03 | — | — | CN | claimed |
| CN-115518058-A | Application of N-cycloalkyl substituted aromatic methylamine compound in preparation of antiviral drug, structure and preparation method | 河北医科大学 | 2022-12-27 | — | — | CN | claimed |
| CN-103391777-A | Sirtuin modulators as virus production modulators | UNIV PRINCETON | 2013-11-13 | — | — | CN | claimed |
| JP-6165646-A | — | — | None | — | — | JP | disclosed |
| US-20230346671-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | NEUERE, LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11730690-B2 | Use of ambroxol to improve skin barrier function | NEUERE, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-116514666-A | Preparation method of bromhexine hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-11583543-B2 | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | NEUERE, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-115677825-A | Degradation agent of target host cell transmembrane serine protease 2 and synthetic method and application thereof | 杭州医学院 | 2023-02-03 | — | — | CN | disclosed |
| CN-115518058-A | Application of N-cycloalkyl substituted aromatic methylamine compound in preparation of antiviral drug, structure and preparation method | 河北医科大学 | 2022-12-27 | — | — | CN | disclosed |
| EP-2361618-A2 | Compositions for treating or preventing obesity and insulin resistance disorders | The President and Fellows of Harvard College (US) | 2011-08-31 | — | — | EP | disclosed |
| CN-101247793-A | Compositions for treating or preventing obesity and insulin resistance disorders | GEN HOSPITAL CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| US-20060292099-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| JP-H06165646-A | CHEMOTHERAPEUTIC COMPOSITION FOR MICROBIAL INFECTIOUS DISEASE OF FISH | BOEHRINGER INGELHEIM VETMEDIKA GMBH | 1994-06-14 | — | — | JP | disclosed |
| EP-0212927-B1 | PHARMACEUTICAL COMPOSITION COMPRISING SODIUM CROMOGLYCATE AND A MUCOLYTIC AGENT | FISONS plc (GB) | 1991-10-23 | — | — | EP | disclosed |
| EP-0212927-A1 | Pharmaceutical composition comprising sodium cromoglycate and a mucolytic agent | FISONS plc (GB) | 1987-03-04 | — | — | EP | disclosed |
| EP-0130224-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-3,5-DIBROMOBENZYL AMINES | LUDWIG HEUMANN & CO GMBH (DE) | 1986-09-10 | — | — | EP | disclosed |
| EP-0130224-A1 | Process for the preparation of 2-amino-3,5-dibromobenzyl amines | LUDWIG HEUMANN & CO GMBH (DE) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346671-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | CUTA, MCOLN3, MMP1 | CYP2D6 1737/4885LMNA 1615/4885CYP1A2 219/4885 |
| US-11583543-B2 | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | BTD, BRD3, GLA | CYP2D6 4244/4885LMNA 1420/4885CYP1A2 1186/4885 |
| US-20060292099-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | CYP2D6 4771/4885LMNA 3964/4885CYP1A2 4117/4885 |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | FABP4, GPR119, SIRT1 | CYP2D6 4876/4885LMNA 937/4885CYP1A2 4720/4885 |
| US-11730690-B2 | Use of ambroxol to improve skin barrier function | CUTA, MCOLN3, MCOLN2 | CYP2D6 1492/4885LMNA 1774/4885CYP1A2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.